Hitto Kaufmann Net Worth

Hitto Kaufmann biography

Dr. Hitto Kaufmann Ph.D. serves as Senior Vice President, Chief Scientific Officer of the Company. Dr. Kaufmann joined Pieris in September 2019 from Sanofi where he was Global Head Strategy and Operations, Sanofi R&D from October 2018 through July 2019, Global Vice President, BioPharmaceutics Development and Platform Innovation, Sanofi R&D from September 2015 through September 2018 and prior to that, Vice President, Technology and Development for Sanofi Biologics from July 2014 through August 2015. At Sanofi, Dr. Kaufmann led the integration of Ablynx into Sanofi’s research and development infrastructure, as well as a global team of over 700 people that was responsible for the development and implementation of drug substance and drug product manufacturing processes for biologics, while spearheading Sanofi’s efforts to harness big data and deploy artificial intelligence to streamline its biologics-based drug discovery efforts. Previously, he was Vice President, Process Science in the Biopharmaceuticals Division of Boehringer Ingelheim from May 2011 to June 2014. He began his career as a Research Scientist at the Walter and Eliza Hall Institute in Melbourne. Dr. Kauffmann received his Ph.D. from the Swiss Federal Institute of Technology in Zurich and pursued his Master studies in Biotechnology at the Technical University of Braunschweig and The Scripps Research Institute.

What is the salary of Hitto Kaufmann?

As the Senior Vice President e Chief Scientific Officer of Pieris Pharmaceuticals Inc, the total compensation of Hitto Kaufmann at Pieris Pharmaceuticals Inc is $1,101,280. There are 1 executives at Pieris Pharmaceuticals Inc getting paid more, with Stephen Yoder having the highest compensation of $1,593,600.

How old is Hitto Kaufmann?

Hitto Kaufmann is 49, he's been the Senior Vice President e Chief Scientific Officer of Pieris Pharmaceuticals Inc since 2019. There are 7 older and 10 younger executives at Pieris Pharmaceuticals Inc. The oldest executive at Pieris Pharmaceuticals Inc is Peter Kiener, 68, who is the Independent Director.

What's Hitto Kaufmann's mailing address?

Hitto's mailing address filed with the SEC is C/O PIERIS PHARMACEUTICALS, INC., 225 FRANKLIN STREET, 26TH FLOOR, BOSTON, MA, 02110.

Insiders trading at Pieris Pharmaceuticals Inc

Over the last 9 years, insiders at Pieris Pharmaceuticals Inc have traded over $24,745,707 worth of Pieris Pharmaceuticals Inc stock and bought 1,154,000 units worth $3,376,410 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Advisors Llc Orbi Med Capit... e Chau Quang Khuong. On average, Pieris Pharmaceuticals Inc executives and independent directors trade stock every 144 days with the average trade being worth of $4,572,148. The most recent stock trade was executed by Capital Management, Llcadar... on 9 August 2024, trading 6,000 units of PIRS stock currently worth $92,340.

What does Pieris Pharmaceuticals Inc do?

pieris pharmaceuticals is a clinical stage biotechnology company that discovers and develops anticalin-based drugs to target validated disease pathways in a unique and transformative way. our pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled anticalin to treat uncontrolled asthma and a half-life-optimized anticalin to treat anemia. proprietary to pieris, anticalin proteins are a novel class of therapeutics validated in the clinic and by partnerships with leading pharmaceutical companies. anticalin proteins are engineered versions of lipocalins, human proteins that naturally bind, store and transport a wide spectrum of molecules. our libraries of more than 100 billion different anticalin proteins have repeatedly delivered drug candidates binding to a very broad spectrum of therapeutic targets. pieris has established a diverse pipeline of anticalin therapeutics for a number of different indications and has r&d collaborations with roche

Pieris Pharmaceuticals Inc executives and stock owners

Pieris Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Stephen Yoder,
  President, Chief Executive Officer, Director
• Hitto Kaufmann,
  Senior Vice President, Chief Scientific Officer
• Stephen S. Yoder J.D.,
  CEO, Pres & Director
• Stephen S. Yoder,
  CEO, Pres & Director
• Dr. Hitto Kaufmann Ph.D.,
  Sr. VP & Chief Scientific Officer
• Dr. Tim Demuth M.D., Ph.D.,
  Sr. VP & Chief Medical Officer
• Thomas Bures,
  Sr. VP & CFO
• james Geraghty,
  Independent Chairman of the Board
• Christopher Kiritsy,
  Independent Director
• Peter Kiener,
  Independent Director
• Matthew Sherman,
  Independent Director
• Michael Richman,
  Independent Director
• Ann Barbier,
  Independent Director
• Maya Said,
  Independent Director
• Maria Kelman,
  Director of Investor Relations
• Shane Olwill,
  Senior Vice President - Head of Translational Science
• Eckhard Niemeier,
  Senior Vice President - Head of Business Development
• Ingmar Bruns,
  Senior Vice President - Head of Clinical Development
• Ahmed Mousa,
  Senior Vice President - Corporate Operations , General Counsel, Secretary
• Thomas Bures,
  Chief Financial Officer, Principal Accounting Officer, Vice President - Finance, Treasurer
• Dr. Shane Olwill Ph.D.,
  Sr. VP & Chief Devel. Officer
• Ahmed S. Mousa J.D.,
  Sr. VP, Chief Bus. Officer, Gen. Counsel & Corp. Sec.
• Prompong Chaikul,
  Chief Supply Chain Officer
• Dr. Christine Rothe,
  Head of Discovery & Alliance Management and VP
• Frank Vollmering,
  VP of HR
• Advisors Llc Orbi Med Capit...,
  
• Jean Pierre Bizzari,
  
• Claude Knopf,
  Chief Business Officer
• Steven Prelack,
  Director
• Julian Adams,
  
• Louis Matis,
  SVP, Chief Development Officer
• Darlene M Deptula Hicks,
  Sr. Vice President and CFO
• Chau Quang Khuong,
  Director
• Advisors Llc Orbi Med Capit...,
  
• Allan Reine,
  Chief Financial Officer
• Partners L P/Ilbiotechnolog...,
  
• Capital Management, Llc Aquilo,
  10% owner
• Tim Demuth,
  Chief Medical Officer
• Capital Management, Llcadar...,